vs
Tonix Pharmaceuticals Holding Corp.（TNXP）与UNITED GUARDIAN INC（UG）财务数据对比。点击上方公司名可切换其他公司
Tonix Pharmaceuticals Holding Corp.的季度营收约是UNITED GUARDIAN INC的1.8倍（$5.4M vs $3.0M），Tonix Pharmaceuticals Holding Corp.同比增速更快（108.8% vs 19.6%），UNITED GUARDIAN INC自由现金流更多（$308.0K vs $-41.5M），过去两年Tonix Pharmaceuticals Holding Corp.的营收复合增速更高（47.4% vs -4.6%）
Tonix Pharmaceuticals是一家总部位于美国新泽西州查塔姆的制药企业，核心业务聚焦于中枢神经系统疾病适应症的再利用药物开发，截至2020年，该公司同时还在开展新冠疫苗研发以及一个生物防御相关项目。
美国守护者人寿保险公司是全球规模领先的相互制人寿保险公司之一，总部位于曼哈顿。公司在美国拥有约8000名员工，在全国70余家机构布局了超过3000名财务顾问的服务网络。2018年，该公司按营收计位列美国财富500强第239位，业内实力雄厚。
TNXP vs UG — 直观对比
营收规模更大
TNXP
是对方的1.8倍
$3.0M
营收增速更快
TNXP
高出89.2%
19.6%
自由现金流更多
UG
多$41.8M
$-41.5M
两年增速更快
TNXP
近两年复合增速
-4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.4M | $3.0M |
| 净利润 | $-46.9M | — |
| 毛利率 | 80.4% | 45.0% |
| 营业利润率 | -895.8% | 24.4% |
| 净利率 | -870.3% | — |
| 营收同比 | 108.8% | 19.6% |
| 净利润同比 | -112.2% | — |
| 每股收益（稀释后） | $-4.28 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TNXPUG
| Q4 25 | $5.4M | $3.0M | ||
| Q3 25 | $3.3M | $2.3M | ||
| Q2 25 | $2.0M | $2.8M | ||
| Q1 25 | $2.4M | $2.5M | ||
| Q4 24 | $2.6M | $2.5M | ||
| Q3 24 | $2.8M | $3.1M | ||
| Q2 24 | $2.2M | $3.4M | ||
| Q1 24 | $2.5M | $3.3M |
净利润TNXPUG
| Q4 25 | $-46.9M | — | ||
| Q3 25 | $-32.0M | $268.4K | ||
| Q2 25 | $-28.3M | $626.8K | ||
| Q1 25 | $-16.8M | $560.9K | ||
| Q4 24 | $-22.1M | — | ||
| Q3 24 | $-14.2M | $865.5K | ||
| Q2 24 | $-78.8M | $956.2K | ||
| Q1 24 | $-14.9M | $925.4K |
毛利率TNXPUG
| Q4 25 | 80.4% | 45.0% | ||
| Q3 25 | 58.4% | 42.1% | ||
| Q2 25 | -63.8% | 52.8% | ||
| Q1 25 | 61.2% | 54.7% | ||
| Q4 24 | 54.2% | 51.7% | ||
| Q3 24 | 44.9% | 54.0% | ||
| Q2 24 | -52.5% | 54.0% | ||
| Q1 24 | 33.1% | 52.2% |
营业利润率TNXPUG
| Q4 25 | -895.8% | 24.4% | ||
| Q3 25 | -1005.1% | 9.5% | ||
| Q2 25 | -1416.2% | 24.5% | ||
| Q1 25 | -660.9% | 24.6% | ||
| Q4 24 | -870.6% | 22.5% | ||
| Q3 24 | -551.2% | 31.0% | ||
| Q2 24 | -3501.6% | 32.9% | ||
| Q1 24 | -860.2% | 31.5% |
净利率TNXPUG
| Q4 25 | -870.3% | — | ||
| Q3 25 | -972.9% | 11.9% | ||
| Q2 25 | -1415.0% | 22.1% | ||
| Q1 25 | -692.8% | 22.6% | ||
| Q4 24 | -856.2% | — | ||
| Q3 24 | -503.6% | 28.3% | ||
| Q2 24 | -3567.8% | 28.2% | ||
| Q1 24 | -601.9% | 28.4% |
每股收益（稀释后）TNXPUG
| Q4 25 | $-4.28 | — | ||
| Q3 25 | $-3.59 | — | ||
| Q2 25 | $-3.86 | — | ||
| Q1 25 | $-2.84 | — | ||
| Q4 24 | $2302.65 | — | ||
| Q3 24 | $-22.68 | — | ||
| Q2 24 | $-1920.85 | — | ||
| Q1 24 | $-535.72 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $207.6M | $8.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $245.2M | $11.2M |
| 总资产 | $277.2M | $13.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TNXPUG
| Q4 25 | $207.6M | $8.6M | ||
| Q3 25 | $190.1M | $8.3M | ||
| Q2 25 | $125.3M | $8.4M | ||
| Q1 25 | $131.7M | $8.1M | ||
| Q4 24 | $98.8M | $9.4M | ||
| Q3 24 | $28.2M | $9.5M | ||
| Q2 24 | $4.2M | $9.9M | ||
| Q1 24 | $7.0M | $8.6M |
总债务TNXPUG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $8.7M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $10.1M | — | ||
| Q1 24 | $10.8M | — |
股东权益TNXPUG
| Q4 25 | $245.2M | $11.2M | ||
| Q3 25 | $231.1M | $10.6M | ||
| Q2 25 | $168.0M | $11.5M | ||
| Q1 25 | $180.4M | $10.8M | ||
| Q4 24 | $139.6M | $11.9M | ||
| Q3 24 | $74.2M | $11.4M | ||
| Q2 24 | $42.1M | $12.1M | ||
| Q1 24 | $108.1M | $11.2M |
总资产TNXPUG
| Q4 25 | $277.2M | $13.1M | ||
| Q3 25 | $252.4M | $12.2M | ||
| Q2 25 | $187.4M | $13.4M | ||
| Q1 25 | $192.9M | $12.8M | ||
| Q4 24 | $162.9M | $13.8M | ||
| Q3 24 | $95.0M | $13.3M | ||
| Q2 24 | $70.3M | $13.8M | ||
| Q1 24 | $135.3M | $13.0M |
负债/权益比TNXPUG
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.13× | — | ||
| Q2 24 | 0.24× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-39.6M | $330.5K |
| 自由现金流经营现金流 - 资本支出 | $-41.5M | $308.0K |
| 自由现金流率自由现金流/营收 | -770.4% | 10.4% |
| 资本支出强度资本支出/营收 | 34.8% | 0.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-103.2M | $1.9M |
8季度趋势，按日历期对齐
经营现金流TNXPUG
| Q4 25 | $-39.6M | $330.5K | ||
| Q3 25 | $-28.8M | $1.0M | ||
| Q2 25 | $-14.8M | $303.2K | ||
| Q1 25 | $-16.6M | $322.1K | ||
| Q4 24 | $-14.6M | $269.3K | ||
| Q3 24 | $-18.8M | $1.2M | ||
| Q2 24 | $-9.9M | $1.3M | ||
| Q1 24 | $-17.6M | $644.1K |
自由现金流TNXPUG
| Q4 25 | $-41.5M | $308.0K | ||
| Q3 25 | $-29.7M | $995.8K | ||
| Q2 25 | $-15.4M | $285.6K | ||
| Q1 25 | $-16.6M | $318.5K | ||
| Q4 24 | $-14.6M | $-45.9K | ||
| Q3 24 | $-18.8M | $1.2M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | $-17.7M | $622.2K |
自由现金流率TNXPUG
| Q4 25 | -770.4% | 10.4% | ||
| Q3 25 | -904.1% | 44.0% | ||
| Q2 25 | -768.8% | 10.1% | ||
| Q1 25 | -682.8% | 12.8% | ||
| Q4 24 | -566.7% | -1.9% | ||
| Q3 24 | -666.5% | 39.2% | ||
| Q2 24 | — | 37.1% | ||
| Q1 24 | -712.4% | 19.1% |
资本支出强度TNXPUG
| Q4 25 | 34.8% | 0.8% | ||
| Q3 25 | 29.2% | 0.7% | ||
| Q2 25 | 26.4% | 0.6% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 0.1% | 12.7% | ||
| Q3 24 | 0.3% | 1.0% | ||
| Q2 24 | 0.0% | 1.9% | ||
| Q1 24 | 4.4% | 0.7% |
现金转化率TNXPUG
| Q4 25 | — | — | ||
| Q3 25 | — | 3.77× | ||
| Q2 25 | — | 0.48× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.38× | ||
| Q1 24 | — | 0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TNXP
| Zembrace Symtouch | $3.1M | 58% |
| Other | $2.3M | 42% |
UG
| Pharmaceuticals | $1.6M | 53% |
| Other | $1.4M | 47% |
